Carter, LM;
Ehrenstein, MR;
Vital, EM;
(2025)
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.
The Lancet Rheumatology
, 7
(5)
e355-e367.
10.1016/S2665-9913(24)00338-2.
![[thumbnail of Figure_1_v2.0.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Figure_1_v2.0.pdf - Accepted Version Access restricted to UCL open access staff until 26 October 2025. Download (22kB) |
|
Text
Figure_2_v2.0.pdf - Accepted Version Access restricted to UCL open access staff until 26 October 2025. Download (553kB) |
|
Text
Figure_3_v2.0.pdf - Accepted Version Access restricted to UCL open access staff until 26 October 2025. Download (552kB) |
|
Text
Ehrenstein_B cell tagetting LancetRheum Review_v3.0_clean.pdf Access restricted to UCL open access staff until 26 October 2025. Download (310kB) |
|
Text
Ehrenstein_Table 1.pdf Access restricted to UCL open access staff until 26 October 2025. Download (140kB) |
Abstract
Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be specifically therapeutically targeted through depletion and have the only therapy with a routinely available flow cytometric biomarker of treatment. Since first use and subsequent licensing for rheumatoid arthritis, rituximab has had a transformative impact on patients globally and across the rheumatic diseases. Further insights from B-cell-activating factor (BAFF) blockade with belimumab in systemic lupus erythematosus have followed. Examination of B-cell depletion, clinical outcomes, and re-emergent disease after treatment have deepened our understanding of the identity, detailed phenotype, biology, and kinetics of the B-cell subsets that are central to disease. This Review reflects on 20 years of clinical and translational insights drawn from B-cell targeted therapies for adult autoimmune rheumatic diseases, and highlights how these therapies have informed an exciting new era of future therapeutic developments.
| Type: | Article |
|---|---|
| Title: | Evolution and trajectory of B-cell targeted therapies in rheumatic diseases |
| Location: | England |
| DOI: | 10.1016/S2665-9913(24)00338-2 |
| Publisher version: | https://doi.org/10.1016/s2665-9913(24)00338-2 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Humans, Rheumatic Diseases, B-Lymphocytes, Rituximab, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Lupus Erythematosus, Systemic, Molecular Targeted Therapy, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, B-Cell Activating Factor |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10211202 |
Archive Staff Only
 |
View Item |
